Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 3/20 | 0.52 |
| ▸ | AXL | P30530 | 4/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | SGK1 | O00141 | 2/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746297 | 0.88 | DYRK1A (0.51) | CDK8AXLTNIKKITDYRK1A | |
| SCHEMBL1801948 | 0.85 | AXL (0.72) | CDK8AXLTNIKKITSGK1 | |
| SCHEMBL8321003 | 0.81 | CAMKK2 (0.68) | CDK8AXLTNIKKITCAMKK2 | |
| SCHEMBL8316949 | 0.81 | CDK8 (0.67) | CDK8AXLTNIKKITDYRK1A | |
| SCHEMBL8323580 | 0.79 | AXL (0.55) | CDK8AXLTNIKKITDYRK1A | |
| SCHEMBL8256242 | 0.79 | CDK8 (0.72) | CDK8AXLTNIKKITDYRK1A | |
| SCHEMBL8320561 | 0.79 | CDK8 (0.49) | CDK8AXLTNIKKITDYRK1A | |
| SCHEMBL8320264 | 0.78 | AXL (0.52) | CDK8AXLTNIKKITDYRK1A | |
| SCHEMBL8320981 | 0.77 | CDK8 (0.73) | CDK8AXLTNIKKITDYRK1A | |
| SCHEMBL8319981 | 0.76 | MAPK8 (0.67) | CDK8AXLTNIKKITDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CDK8 360/4885AXL 3999/4885TNIK 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.